Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K, et al. The global landscape of approved antibody therapies. Antib Ther. 2022;5(4):233–57.
CAS PubMed PubMed Central Google Scholar
Walsh G, Walsh E. Biopharmaceutical benchmarks. Nat Biotechnol. 2022;2022:1–39.
Rathore AS, Chirmule N, Malani H. Reimagining affordable biosimilars. Biopharm Int. 2020;33(10):16–22.
Wang W, Roberts CJ. Protein aggregation—mechanisms, detection, and control. Int J Pharm. 2018;550(1–2):251–68.
Article CAS PubMed Google Scholar
Singla A, Bansal R, Joshi V, Rathore AS. Aggregation kinetics for IgG1-based monoclonal antibody therapeutics. AAPS J. 2016;18(3):689–702.
Article CAS PubMed PubMed Central Google Scholar
Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291–305.
Article CAS PubMed Google Scholar
Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28(3):608–22.
Article CAS PubMed Google Scholar
Beck A, Liu H. Macro-and micro-heterogeneity of natural and recombinant IgG antibodies. Antibodies. 2019;8(1):18.
Article CAS PubMed PubMed Central Google Scholar
Singh SK, Kumar D, Rathore AS. Determination of critical quality attributes for a biotherapeutic in the QbD paradigm: GCSF as a case study. AAPS J. 2017;19:1826–41.
Article CAS PubMed Google Scholar
Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14:554–8.
Article CAS PubMed PubMed Central Google Scholar
Pham NB, Meng WS. Protein aggregation and immunogenicity of biotherapeutics. Int J Pharm. 2020;585: 119523.
Article CAS PubMed PubMed Central Google Scholar
Rudge SR, Nims RW. ICH Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products. ICH Quality Guidelines: An Implementation Guide. 2017;467–86.
Kayser V, Chennamsetty N, Voynov V, Helk B, Forrer K, Trout BL. Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharm Sci. 2011;100(7):2526–42.
Article CAS PubMed Google Scholar
Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109(1):169–90.
Kaur H. Stability testing in monoclonal antibodies. Crit Rev Biotechnol. 2021;41(5):692–714.
Article CAS PubMed Google Scholar
Vázquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108(7):1494–508.
Meyer RM, Berger L, Nerkamp J, Scheler S, Nehring S, Friess W. Identification of monoclonal antibody variants involved in aggregate formation—part 1: charge variants. Eur J Pharm Biopharm. 2021;158:123–31.
Article CAS PubMed Google Scholar
Meyer RM, Berger L, Nerkamp J, Scheler S, Nehring S, Friess W. Identification of monoclonal antibody variants involved in aggregate formation—part 2: hydrophobicity variants. Eur J Pharm Biopharm. 2021;160:134–42.
Article CAS PubMed Google Scholar
Courtois F, Agrawal NJ, Lauer TM, Trout BL. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. In: MAbs. Taylor & Francis; 2016;8(1):99–112.
Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. In: MAbs. Taylor & Francis; 2012;4(5):578–85.
Yüce M, Sert F, Torabfam M, Parlar A, Gürel B, Çakır N, et al. Fractionated charge variants of biosimilars: a review of separation methods, structural and functional analysis. Anal Chim Acta. 2021;1152: 238189.
Beck A, Nowak C, Meshulam D, Reynolds K, Chen D, Pacardo DB, et al. Risk-based control strategies of recombinant monoclonal antibody charge variants. Antibodies. 2022;11(4):73.
Article CAS PubMed PubMed Central Google Scholar
Gervais D. Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. J Chem Technol Biotechnol. 2016;91(3):569–75.
Yan Q, Huang M, Lewis MJ, Hu P. Structure based prediction of asparagine deamidation propensity in monoclonal antibodies. In: MAbs. Taylor & Francis; 2018;10(6):901–12.
Alam ME, Barnett GV, Slaney TR, Starr CG, Das TK, Tessier PM. Deamidation can compromise antibody colloidal stability and enhance aggregation in a pH-dependent manner. Mol Pharm. 2019;16(5):1939–49.
Article CAS PubMed Google Scholar
Faid V, Leblanc Y, Berger M, Seifert A, Bihoreau N, Chevreux G. C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors. Eur J Pharm Sci. 2021;159: 105730.
Article CAS PubMed Google Scholar
Joshi VS, Kumar V, Rathore AS. Enhanced product understanding in the QbD paradigm: linkage between charge heterogeneity and stability of monoclonal antibody therapeutic products. J Chem Technol Biotechnol. 2018;93(8):2102–10.
Spanov B, Olaleye O, Lingg N, Bentlage AEH, Govorukhina N, Hermans J, et al. Change of charge variant composition of trastuzumab upon stressing at physiological conditions. J Chromatogr A. 2021;1655: 462506.
Article CAS PubMed Google Scholar
Meyer RM, Aleshkevich S, Berger L, Nerkamp J, Scheler S, Friess W. Characterization of the aggregation propensity of charge variants of recombinant human growth hormone. Int J Pharm. 2022;621: 121760.
Article CAS PubMed Google Scholar
Joshi V, Shivach T, Kumar V, Yadav N, Rathore A. Avoiding antibody aggregation during processing: establishing hold times. Biotechnol J. 2014;9(9):1195–205.
Article CAS PubMed Google Scholar
Wälchli R, Vermeire PJ, Massant J, Arosio P. Accelerated aggregation studies of monoclonal antibodies: considerations for storage stability. J Pharm Sci. 2020;109(1):595–602.
Joshi S, Rathore AS. Assessment of structural and functional comparability of biosimilar products: trastuzumab as a case study. BioDrugs. 2020;34:209–23.
Article CAS PubMed Google Scholar
Singh SK, Kumar D, Malani H, Rathore AS. LC–MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity. Sci Rep. 2021;11(1):2487.
Levenspiel O. Chemical reaction engineering. John Wiley & Sons; 1998.
Shrivastava A, Mandal S, Pattanayek SK, Rathore AS. Rapid estimation of size-based heterogeneity in monoclonal antibodies by machine learning-enhanced dynamic light scattering. Anal Chem. 2023;95(21):8299–309.
Schmid I, Bonnington L, Gerl M, Bomans K, Thaller AL, Wagner K, et al. Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions. Commun Biol. 2018;1(1):28.
Article PubMed PubMed Central Google Scholar
Gupta S, Upadhyay K, Schöneich C, Rathore AS. Impact of various factors on the kinetics of non-enzymatic fragmentation of a monoclonal antibody. Eur J Pharm Biopharm. 2022;178:131–9.
Article CAS PubMed Google Scholar
Fincke A, Winter J, Bunte T, Olbrich C. Thermally induced degradation pathways of three different antibody-based drug development candidates. Eur J Pharm Sci. 2014;62:148–60.
Article CAS PubMed Google Scholar
Rajagopal K, Chang D, Nayak P, Izadi S, Patapoff T, Zhang J, et al. Trehalose limits fragment antibody aggregation and influences charge variant formation in spray-dried formulations at elevated temperatures. Mol Pharm. 2018;16(1):349–58.
Jaccoulet E, Daniel T, Prognon P, Caudron E. Forced degradation of monoclonal antibodies after compounding: impact on routine hospital quality control. J Pharm Sci. 2019;108(10):3252–61.
Article CAS PubMed Google Scholar
Shieh IC, Patel AR. Predicting the agitation-induced aggregation of monoclonal antibodies using surface tensiometry. Mol Pharm. 2015;12(9):3184–93.
Article CAS PubMed Google Scholar
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs. 2010;2(6):613–24.
Article PubMed PubMed Central Google Scholar
Singh SK, Kumar D, Nagpal S, Dubey SK, Rathore AS. A charge variant of bevacizumab offers enhanced FcRn-dependent pharmacokinetic half-life and efficacy. Pharm Res. 2022;39(5):851–65.
Article CAS PubMed Google Scholar
Singh SK, Narula G, Rathore AS. Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes? Electroph
Comments (0)